{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:39:37Z","timestamp":1789421977557,"version":"build-2803163510"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-026-01452-6","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:58:51Z","timestamp":1777863531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Searching for immune correlates in Lassa vaccine development \u2013 workshop report"],"prefix":"10.1038","volume":"11","author":[{"given":"Trevor","family":"Brasel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Brangel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ifedayo","family":"Adetifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Baize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Benkeser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bertoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Bukreyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Charlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Cramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles P.","family":"Davenport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devy","family":"Emperador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Formenty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Follmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Garry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy D.","family":"Gollihar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C.","family":"Grassly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati B.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Hacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Hoath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Holbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Killip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henshaw","family":"Mandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent J.","family":"Munster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christinah","family":"Mukandavire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Oestereich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvanus","family":"Okogbenin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Oloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slobodan","family":"Paessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Richert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Safronetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica Ollmann","family":"Saphire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Sette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Shurtleff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Granerod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Zaric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Ramsauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Dahlke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"1452_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47820-3","volume":"13","author":"S Cadmus","year":"2023","unstructured":"Cadmus, S. et al. Ecological correlates and predictors of Lassa fever incidence in Ondo State, Nigeria 2017-2021: an emerging urban trend. Sci. Rep. 13, 20855 (2023).","journal-title":"Sci. Rep."},{"key":"1452_CR2","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/infdis\/155.3.445","volume":"155","author":"JB McCormick","year":"1987","unstructured":"McCormick, J. B. et al. A case-control study of the clinical diagnosis and course of Lassa fever. J. Infect. Dis. 155, 445\u2013455 (1987).","journal-title":"J. Infect. Dis."},{"key":"1452_CR3","unstructured":"Africa Centres for Disease Control and Prevention. Lassa fever [Internet]. [cited 2026 Mar 26]. Report No. Available from: https:\/\/africacdc.org\/disease\/lassa-fever\/#:~:text=The%20signs%20and%20symptoms%20of,and%20abdominal%20pain%20may%20follow."},{"key":"1452_CR4","first-page":"1352","volume":"71","author":"L Pinneo","year":"1971","unstructured":"Pinneo, L. & Pinneo, R. Mystery virus from Lassa. Am. J. Nurs. 71, 1352\u20131355 (1971).","journal-title":"Am. J. Nurs."},{"key":"1452_CR5","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/227174a0","volume":"227","author":"SM Buckley","year":"1970","unstructured":"Buckley, S. M., Casals, J. & Downs, W. G. Isolation and antigenic characterization of Lassa virus. Nature 227, 174 (1970).","journal-title":"Nature"},{"key":"1452_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1126\/science.185.4147.263","volume":"185","author":"TP Monath","year":"1974","unstructured":"Monath, T. P., Newhouse, V. F., Kemp, G. E., Setzer, H. W. & Cacciapuoti, A. Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone. Science 185, 263\u2013265 (1974).","journal-title":"Science"},{"key":"1452_CR7","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1136\/bmj.297.6648.584","volume":"297","author":"ME Price","year":"1988","unstructured":"Price, M. E., Fisher-Hoch, S. P., Craven, R. B. & McCormick, J. B. A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy. BMJ 297, 584\u2013587 (1988).","journal-title":"BMJ"},{"key":"1452_CR8","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S1473-3099(18)30121-X","volume":"18","author":"P Okokhere","year":"2018","unstructured":"Okokhere, P. et al. Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study. Lancet Infect. Dis. 18, 684\u2013695 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"1452_CR9","doi-asserted-by":"crossref","unstructured":"Moore, K. A. et al. Lassa fever research priorities: towards effective medical countermeasures by the end of the decade. Lancet Infect. Dis. 24, e696-e706 (2024).","DOI":"10.1016\/S1473-3099(24)00229-9"},{"key":"1452_CR10","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1038\/s41591-024-03232-y","volume":"30","author":"DRM Smith","year":"2024","unstructured":"Smith, D. R. M. et al. Health and economic impacts of Lassa vaccination campaigns in West Africa. Nat. Med. 30, 3568\u20133577 (2024).","journal-title":"Nat. Med."},{"key":"1452_CR11","unstructured":"World Health Organization. Pathogens prioritization - A scientific framework for epidemic and pandemic research preparedness [Internet]. Geneva, Switzerland; 2024 [cited 2025 Apr 9]. Report No. Available from: https:\/\/cdn.who.int\/media\/docs\/default-source\/consultation-rdb\/prioritization-pathogens-v6final.pdf?sfvrsn=c98effa7_7&download=true."},{"key":"1452_CR12","doi-asserted-by":"crossref","unstructured":"Garry, R. F. Lassa fever - the road ahead. Nat. Rev. Microbiol. 21, 87\u201396 (2023).","DOI":"10.1038\/s41579-022-00789-8"},{"key":"1452_CR13","doi-asserted-by":"crossref","unstructured":"Fichet-Calvet, E. The role of animals in emerging viral diseases. In Lassa Fever: A Rodent-human Interaction Ch. 5, 89\u2013123 (Academic Press, 2014). Available from: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/B9780124051911000053?via%3Dihub.","DOI":"10.1016\/B978-0-12-405191-1.00005-3"},{"key":"1452_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112524","volume":"42","author":"HR Perrett","year":"2023","unstructured":"Perrett, H. R. et al. Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies. Cell Rep. 42, 112524 (2023).","journal-title":"Cell Rep."},{"key":"1452_CR15","doi-asserted-by":"publisher","first-page":"e1005418","DOI":"10.1371\/journal.ppat.1005418","volume":"12","author":"S Li","year":"2016","unstructured":"Li, S. et al. Acidic pH-induced conformations and LAMP1 binding of the Lassa virus glycoprotein spike. PLoS Pathog. 12, e1005418 (2016).","journal-title":"PLoS Pathog."},{"key":"1452_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.coviro.2018.05.002","volume":"31","author":"KM Hastie","year":"2018","unstructured":"Hastie, K. M. & Saphire, E. O. Lassa virus glycoprotein: stopping a moving target. Curr. Opin. Virol. 31, 52\u201358 (2018).","journal-title":"Curr. Opin. Virol."},{"key":"1452_CR17","doi-asserted-by":"publisher","unstructured":"Pennington, H. N. & Lee, J. Lassa virus glycoprotein complex review: insights into its unique fusion machinery. Biosci. Rep. 42, https:\/\/doi.org\/10.1042\/BSR20211930 (2022).","DOI":"10.1042\/BSR20211930"},{"key":"1452_CR18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s004300100061","volume":"189","author":"S G\u00fcnther","year":"2001","unstructured":"G\u00fcnther, S. et al. Antibodies to Lassa virus Z protein and nucleoprotein co-occur in human sera from Lassa fever endemic regions. Med. Microbiol. Immunol. 189, 225\u2013229 (2001).","journal-title":"Med. Microbiol. Immunol."},{"key":"1452_CR19","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.3390\/v4112766","volume":"4","author":"M Russier","year":"2012","unstructured":"Russier, M., Pannetier, D. & Baize, S. Immune responses and Lassa virus infection. Viruses 4, 2766\u20132785 (2012).","journal-title":"Viruses"},{"key":"1452_CR20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2016.138","volume":"17","author":"JB Prescott","year":"2017","unstructured":"Prescott, J. B. et al. Immunobiology of Ebola and Lassa virus infections. Nat. Rev. Immunol. 17, 195\u2013207 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"1452_CR21","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1186\/1743-422X-8-478","volume":"8","author":"LM Branco","year":"2011","unstructured":"Branco, L. M. et al. Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection. Virol. J. 8, 478 (2011).","journal-title":"Virol. J."},{"key":"1452_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44534-y","volume":"15","author":"J Gorman","year":"2024","unstructured":"Gorman, J. et al. Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability. Nat. Commun. 15, 285 (2024).","journal-title":"Nat. Commun."},{"key":"1452_CR23","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1126\/science.aam7260","volume":"356","author":"KM Hastie","year":"2017","unstructured":"Hastie, K. M. et al. Structural basis for antibody-mediated neutralization of Lassa virus. Science 356, 923\u2013928 (2017).","journal-title":"Science"},{"key":"1452_CR24","doi-asserted-by":"publisher","unstructured":"Port, J. R. et al. Severe human lassa fever is characterized by nonspecific T-cell activation and lymphocyte homing to inflamed tissues. J. Virol. 94, https:\/\/doi.org\/10.1128\/JVI.01367-20 (2020).","DOI":"10.1128\/JVI.01367-20"},{"key":"1452_CR25","doi-asserted-by":"publisher","first-page":"e0010882","DOI":"10.1371\/journal.pntd.0010882","volume":"16","author":"SM LaVergne","year":"2022","unstructured":"LaVergne, S. M. et al. Expansion of CD8+ T cell population in Lassa virus survivors with low T cell precursor frequency reveals durable immune response in most survivors. PLoS Negl. Trop. Dis. 16, e0010882 (2022).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1452_CR26","doi-asserted-by":"publisher","first-page":"e0283643","DOI":"10.1371\/journal.pone.0283643","volume":"18","author":"S Penfold","year":"2023","unstructured":"Penfold, S. et al. A prospective, multi-site, cohort study to estimate incidence of infection and disease due to Lassa fever virus in West African countries (the Enable Lassa research programme)-Study protocol. PloS ONE 18, e0283643 (2023).","journal-title":"PloS ONE"},{"key":"1452_CR27","doi-asserted-by":"publisher","first-page":"e001960","DOI":"10.1136\/bmjph-2024-001960","volume":"3","author":"H Mandi","year":"2025","unstructured":"Mandi, H. et al. Prospective cohort study to evaluate Lassa fever incidence, symptoms and coinfection with malaria in West Africa: the Enable Lassa Research Programme (\u2018ENABLE 1.5\u2019) - study protocol. BMJ Public Health 3, e001960 (2025).","journal-title":"BMJ Public Health"},{"key":"1452_CR28","doi-asserted-by":"crossref","unstructured":"Sattler, R. A., Paessler, S., Ly, H. & Huang, C. Animal models of Lassa fever. Pathogens 9, 197 (2020).","DOI":"10.3390\/pathogens9030197"},{"key":"1452_CR29","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.coviro.2019.07.005","volume":"37","author":"TL Tang-Huau","year":"2019","unstructured":"Tang-Huau, T. L., Feldmann, H. & Rosenke, K. Animal models for Lassa virus infection. Curr. Opin. Virol. 37, 112\u2013117 (2019).","journal-title":"Curr. Opin. Virol."},{"key":"1452_CR30","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1128\/JVI.02948-15","volume":"90","author":"NE Yun","year":"2015","unstructured":"Yun, N. E. et al. Animal model of sensorineural hearing loss associated with Lassa virus infection. J. Virol. 90, 2920\u20132927 (2015).","journal-title":"J. Virol."},{"key":"1452_CR31","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1093\/infdis\/jiac028","volume":"226","author":"JR Spengler","year":"2022","unstructured":"Spengler, J. R. et al. Lassa virus replicon particle vaccine protects strain 13\/N guinea pigs against challenge with geographically and genetically diverse viral strains. J. Infect. Dis. 226, 1545\u20131550 (2022).","journal-title":"J. Infect. Dis."},{"key":"1452_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/srep14775","volume":"5","author":"D Safronetz","year":"2015","unstructured":"Safronetz, D. et al. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. Sci. Rep. 5, 14775 (2015).","journal-title":"Sci. Rep."},{"key":"1452_CR33","doi-asserted-by":"crossref","unstructured":"Deschambault, Y. et al. An outbred guinea pig disease model for Lassa fever using a host-adapted clade III Nigerian Lassa virus. Viruses 15, 769 (2023).","DOI":"10.3390\/v15030769"},{"key":"1452_CR34","doi-asserted-by":"crossref","unstructured":"Maruyama, J. et al. Lethal infection of Lassa virus isolated from a human clinical sample in outbred Guinea Pigs without adaptation. mSphere 4, e00428-19 (2019).","DOI":"10.1128\/mSphere.00428-19"},{"key":"1452_CR35","doi-asserted-by":"crossref","unstructured":"Downs, I. L. et al. Natural history of aerosol induced Lassa fever in non\u2011human primates. Viruses 12, 593 (2020).","DOI":"10.3390\/v12060593"},{"key":"1452_CR36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/1743-422X-8-205","volume":"8","author":"LE Hensley","year":"2011","unstructured":"Hensley, L. E. et al. Pathogenesis of Lassa fever in cynomolgus macaques. Virol. J. 8, 205 (2011).","journal-title":"Virol. J."},{"key":"1452_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111094","volume":"40","author":"RW Cross","year":"2022","unstructured":"Cross, R. W. et al. A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa fever. Cell Rep. 40, 111094 (2022).","journal-title":"Cell Rep."},{"key":"1452_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101392","volume":"5","author":"RW Cross","year":"2024","unstructured":"Cross, R. W. et al. Monoclonal antibody therapy protects nonhuman primates against mucosal exposure to Lassa virus. Cell Rep. Med. 5, 101392 (2024).","journal-title":"Cell Rep. Med."},{"key":"1452_CR39","doi-asserted-by":"publisher","first-page":"e001116","DOI":"10.1136\/bmjgh-2018-001116","volume":"4","author":"LT Mazzola","year":"2019","unstructured":"Mazzola, L. T. & Kelly-Cirino, C. Diagnostics for Lassa fever virus: a genetically diverse pathogen found in low-resource settings. BMJ Glob. Health 4, e001116 (2019).","journal-title":"BMJ Glob. Health"},{"key":"1452_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2025.117151","volume":"114","author":"L Mazzola","year":"2026","unstructured":"Mazzola, L. et al. Landscape analysis of Lassa virus diagnostic tests: Challenges, innovations and future directions. Diagn. Microbiol. Infect. Dis. 114, 117151 (2026).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"1452_CR41","unstructured":"FIND. [Internet]. [cited 2025 Mar 11]. Available from: https:\/\/finddx.shinyapps.io\/testdirexplorer_beta\/."},{"key":"1452_CR42","unstructured":"Mattiuzzo, G. et al. Establishment of the first WHO International Standard and Reference Panel for anti-Lassa Fever virus antibody. 2021, WHO Expert Committee on Biological Standardization. WHO\/BS\/2021.2406 [Internet]. 2021 [cited 2025 Mar 19]. Report No. Available from: https:\/\/cdn.who.int\/media\/docs\/default-source\/biologicals\/call-for-comments\/bs.2021.2406_who-1st-is-lassa-fever-virus-antibody.pdf?sfvrsn=f6f99f5c_5&download=true."},{"key":"1452_CR43","doi-asserted-by":"publisher","unstructured":"Samandari, T. et al. Prevalence and functional profile of SARS-CoV-2 T cells in asymptomatic Kenyan adults. J. Clin. Investig. 133, https:\/\/doi.org\/10.1172\/JCI170011 (2023).","DOI":"10.1172\/JCI170011"},{"key":"1452_CR44","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41564-024-01903-7","volume":"10","author":"S Kalimuddin","year":"2025","unstructured":"Kalimuddin, S. et al. Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humans. Nat. Microbiol. 10, 374\u2013387 (2025).","journal-title":"Nat. Microbiol."},{"key":"1452_CR45","doi-asserted-by":"publisher","unstructured":"Tan, A. T. et al. Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals. J. Clin. Investig. 131. https:\/\/doi.org\/10.1172\/JCI152379 (2021).","DOI":"10.1172\/JCI152379"},{"key":"1452_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41376-6","volume":"14","author":"AJ Ronk","year":"2023","unstructured":"Ronk, A. J. et al. A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infection. Nat. Commun. 14, 5603 (2023).","journal-title":"Nat. Commun."},{"key":"1452_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00291-x","volume":"6","author":"RJ Fischer","year":"2021","unstructured":"Fischer, R. J. et al. ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge. npj Vaccines 6, 32 (2021).","journal-title":"npj Vaccines"},{"key":"1452_CR48","doi-asserted-by":"publisher","first-page":"6824","DOI":"10.1016\/j.vaccine.2019.09.030","volume":"37","author":"J Maruyama","year":"2019","unstructured":"Maruyama, J. et al. Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs. Vaccine 37, 6824\u20136831 (2019).","journal-title":"Vaccine"},{"key":"1452_CR49","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0140-6736(87)90767-7","volume":"2","author":"JC Clegg","year":"1987","unstructured":"Clegg, J. C. & Lloyd, G. Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever. Lancet Lond. Engl. 2, 186\u2013188 (1987).","journal-title":"Lancet Lond. Engl."},{"key":"1452_CR50","doi-asserted-by":"publisher","first-page":"6777","DOI":"10.1128\/JVI.74.15.6777-6783.2000","volume":"74","author":"SP Fisher-Hoch","year":"2000","unstructured":"Fisher-Hoch, S. P., Hutwagner, L., Brown, B. & McCormick, J. B. Effective vaccine for Lassa fever. J. Virol. 74, 6777\u20136783 (2000).","journal-title":"J. Virol."},{"key":"1452_CR51","doi-asserted-by":"publisher","first-page":"e0338128","DOI":"10.1371\/journal.pone.0338128","volume":"20","author":"A Bardach","year":"2025","unstructured":"Bardach, A. et al. Efficacy, safety, and immunogenicity of Lassa fever vaccines: a living systematic review and landscape analysis of vaccine candidates. PloS ONE 20, e0338128 (2025).","journal-title":"PloS ONE"},{"key":"1452_CR52","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12985-024-02585-7","volume":"21","author":"BM Warner","year":"2024","unstructured":"Warner, B. M., Safronetz, D. & Stein, D. R. Current perspectives on vaccines and therapeutics for Lassa Fever. Virol. J. 21, 320 (2024).","journal-title":"Virol. J."},{"key":"1452_CR53","doi-asserted-by":"publisher","unstructured":"Carnec, X. et al. A vaccine platform against arenaviruses based on a recombinant hyperattenuated mopeia virus expressing heterologous glycoproteins. J. Virol. 92, https:\/\/doi.org\/10.1128\/JVI.02230-17 (2018).","DOI":"10.1128\/JVI.02230-17"},{"key":"1452_CR54","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw3163","volume":"11","author":"M Mateo","year":"2019","unstructured":"Mateo, M. et al. Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot. Sci. Transl. Med. 11, eaaw3163 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1452_CR55","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf6348","volume":"13","author":"M Mateo","year":"2021","unstructured":"Mateo, M. et al. A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains. Sci. Transl. Med. 13, eabf6348 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1452_CR56","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1371\/journal.pmed.0020183","volume":"2","author":"TW Geisbert","year":"2005","unstructured":"Geisbert, T. W. et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2, e183 (2005).","journal-title":"PLoS Med."},{"key":"1452_CR57","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1056\/NEJMoa2501073","volume":"393","author":"E Malkin","year":"2025","unstructured":"Malkin, E. et al. Safety and immunogenicity of an rVSV Lassa fever vaccine candidate. N. Engl. J. Med. 393, 1807\u20131818 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1452_CR58","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1080\/21645515.2017.1383575","volume":"13","author":"K Ewer","year":"2017","unstructured":"Ewer, K. et al. Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. Hum. Vaccines Immunother. 13, 3020\u20133032 (2017).","journal-title":"Hum. Vaccines Immunother."},{"key":"1452_CR59","unstructured":"PADOVAX - Lassa overview [Internet]. [cited 2024 Jul 3]. Available from: https:\/\/cdn.who.int\/media\/docs\/default-source\/blue-print\/day1_session2_3_sarah-gilbert_lassa-vaccine-meeting_nigeria.pdf?sfvrsn=48bb6ea9_3."},{"key":"1452_CR60","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1086\/522428","volume":"196","author":"L Qin","year":"2007","unstructured":"Qin, L., Gilbert, P. B., Corey, L., McElrath, M. J. & Self, S. G. A framework for assessing immunological correlates of protection in vaccine trials. J. Infect. Dis. 196, 1304\u20131312 (2007).","journal-title":"J. Infect. Dis."},{"key":"1452_CR61","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/cid\/cis238","volume":"54","author":"SA Plotkin","year":"2012","unstructured":"Plotkin, S. A. & Gilbert, P. B. Nomenclature for immune correlates of protection after vaccination. Clin. Infect. Dis. Publ. Infect. Dis. Soc. Am. 54, 1615\u20131617 (2012).","journal-title":"Clin. Infect. Dis. Publ. Infect. Dis. Soc. Am."},{"key":"1452_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.07.035","volume":"42","author":"DN Fisman","year":"2024","unstructured":"Fisman, D. N., Simmons, A. E. & Tuite, A. R. Case-cohort design as an efficient approach to evaluating COVID-19 vaccine effectiveness, waning, heterologous immune effect and optimal dosing interval. Vaccine 42, 126134 (2024).","journal-title":"Vaccine"},{"key":"1452_CR63","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.abm3425","volume":"375","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43\u201350 (2022).","journal-title":"Science"},{"key":"1452_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/biomet\/73.1.1","volume":"73","author":"R Prentice","year":"1986","unstructured":"Prentice, R. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 73, 1\u201311 (1986).","journal-title":"Biometrika"},{"key":"1452_CR65","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S1473-3099(14)70822-9","volume":"14","author":"NJ Andrews","year":"2014","unstructured":"Andrews, N. J. et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect. Dis. 14, 839\u2013846 (2014).","journal-title":"Lancet Infect. Dis."},{"key":"1452_CR66","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1086\/422531","volume":"190","author":"JT Jokinen","year":"2004","unstructured":"Jokinen, J. T., Ahman, H., Kilpi, T. M., M\u00e4kel\u00e4, P. H. & K\u00e4yhty, M. H. Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media. J. Infect. Dis. 190, 545\u2013550 (2004).","journal-title":"J. Infect. Dis."},{"key":"1452_CR67","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1056\/NEJMoa1505819","volume":"373","author":"DE Neafsey","year":"2015","unstructured":"Neafsey, D. E. et al. Genetic diversity and protective efficacy of the RTS,S\/AS01 Malaria Vaccine. N. Engl. J. Med. 373, 2025\u20132037 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1452_CR68","doi-asserted-by":"publisher","first-page":"E8378","DOI":"10.1073\/pnas.1714250115","volume":"115","author":"M Juraska","year":"2018","unstructured":"Juraska, M. et al. Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials. Proc. Natl. Acad. Sci. USA 115, E8378\u2013E8387 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1452_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46536-w","volume":"15","author":"CA Magaret","year":"2024","unstructured":"Magaret, C. A. et al. Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features. Nat. Commun. 15, 2175 (2024).","journal-title":"Nat. Commun."},{"key":"1452_CR70","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/infdis\/jiae090","volume":"230","author":"KM Sumner","year":"2024","unstructured":"Sumner, K. M. et al. Anti-SARS-CoV-2 antibody levels associated with COVID-19 protection in outpatients tested for SARS-CoV-2, US flu vaccine effectiveness network, October 2021-June 2022. J. Infect. Dis. 230, 45\u201354 (2024).","journal-title":"J. Infect. Dis."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01452-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01452-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01452-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T09:04:01Z","timestamp":1777885441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01452-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1452"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01452-6","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"20 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.D.G. is listed as an inventor in patents relating to Lassa fever virus immunogens and have commercially licensed the technologies. AS is a consultant for AstraZeneca, Darwin Health, Desna Therapeutics, Geovax, Link Campus University, RiverVest Venture Partners, and Wugen. LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work. A.S. is part of the Editorial Board of Nature Vaccines NPJ. A.S. was not involved in the journal\u2019s review of, or decisions related to this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}